Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey
Articles > Article · 2016
Authors: Fusun Gediz, Bahriye Kadriye Payzin, Sertac Ecemis, Naile Guler, Asu Fergun Yilmaz, Fusun Topcugil, Afig BERDELİ
Transfusion and Apheresis Science, Journal Indexed in SCI Expanded, International, WoS, 2016, vol 55, pp 357-362
DOI: 10.1016/j.transci.2016.09.017
Summary
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy, which develops as a result of defective activity of the alternative complement pathway and excessive complement activation due to genetic or acquired factors. No satisfactory responses were obtained by plasmapheresis, corticosteroids and fresh frozen plasma (FFP) transfusion. However, promising results are obtained in recent years by eculuzimab treatment, which inhibits C5 activation.